Gulati, Anil http://orcid.org/0000-0002-7420-4554
Choudhuri, Rajat
Gupta, Ajay
Singh, Saurabh
Ali, S. K. Noushad
Sidhu, Gursaran Kaur
Haque, Parvez David
Rahate, Prashant
Bothra, Aditya R.
Singh, Gyan P.
Maheshwari, Sanjiv
Jeswani, Deepak
Haveri, Sameer
Agarwal, Apurva
Agrawal, Nilesh Radheshyam
Clinical trials referenced in this document:
Documents that mention this clinical trial
A Multicentric, Randomized, Controlled Phase III Study of Centhaquine (Lyfaquin®) as a Resuscitative Agent in Hypovolemic Shock Patients
https://doi.org/10.1007/s40265-021-01547-5
Article History
Accepted: 25 May 2021
First Online: 1 June 2021
Declarations
:
: Pharmazz, Inc. Willowbrook, IL, USA, provided funding for this study and paid the open access fee.
: Anil Gulati has issued and pending patents and is an employee and stockholder of Pharmazz, Inc. Rajat Choudhuri, Ajay Gupta, Saurabh Singh, S.K. Noushad Ali, Gursaran Kaur Sidhu, Parvez David Haque, Prashant Rahate, Aditya R. Bothra, Gyan P. Singh, Sanjiv Maheshwari, Deepak Jeswani, Sameer Haveri, Apurva Agarwal, and Nilesh Radheshyam Agrawal have no conflicts of interest that are directly relevant to the content of this article.
: The study protocol (PMZ-2010/CT-3.1/2018) dated July 16, 2018, was approved by the Drugs Controller General of India (DCGI), Directorate General of Health Services, Ministry of Health & Family Welfare, Government of India (DCGI CT NOC. No.: CT/ND/66/2018). Furthermore, each institutional ethics committee reviewed and approved the study protocol before initiating patient enrolment.
: Written informed consent was obtained from all patients or their legally authorized representatives.
: The anonymized patient datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request from a bona fide researcher/research group.
: Study concept and design: AG; investigation: RC, AG, SS, SKNA, GKS, PDH, PR, ARB, GPS, SM, DJ, SH, AA, and NRA; acquisition of data: RC, AG, SS, SKNA, GKS, PDH, PR, ARB, GPS, SM, DJ, SH, AA, and NRA; analysis and interpretation of data: AG; drafting of the manuscript: AG; review of the manuscript: RC, AG, SS, SKNA, GKS, PDH, PR, ARB, GPS, SM, DJ, SH, AA, and NRA; funding acquisition: AG.